Something I received from Edison
Arrowhead Research - New drug candidate revealedClick for report
Arrowhead announced at its recent analyst day its new RNAi-based drug candidate, ARC-AAT, which is developed for alpha-1 antitrypsin deficiency (AATD). ARC-AAT consists of Arrowhead’s unique DPC delivery vehicle and an RNAi molecule based on a new RNA chemistry, and is able to achieve over 95% knockdown of the target protein in animal models. Arrowhead plans to file an IND of ARC-AAT in Q414, right after the release of its top-line results of the Phase IIa trial of ARC-520 in patients with chronic HBV infection in Q314. Our valuation is $1,075m, equivalent to $20.7/per basic share (or $17.3/per diluted share).
Arrowhead Research is a clinical-stage RNAi company with development programmes in chronic hepatitis B virus (HBV) infection, and rare diseases. Its lead product candidate is ARC-520 (Phase IIa) for HBV based on a proprietary delivery technology called dynamic polyconjugate (DPC). Its second drug candidate, ARC-AAT, will enter clinical trials in Q414.